On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration Agreement and License Agreement to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine.

The collaboration combines IDRI’s RNA vaccine platform, including IDRI’s proprietary nanostructured lipid carrier (NLC) platform, with Amyris’s semi-synthetic squalene.